#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Hepatocellular carcinoma Dementia Alzheimer's type Asthma Dermatitis atopic Breast cancer metastatic Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Breast angiosarcoma metastatic Transient ischaemic attack Vulval cancer Congenital disorder of glycosylation Sarcoidosis Colorectal cancer metastatic Isodicentric chromosome 15 syndrome Neuroblastoma recurrent Osteosarcoma Conjunctivitis allergic Infective uveitis Metastatic gastric cancer Waldenstrom's macroglobulinaemia recurrent Brain stem glioma Chronic lymphocytic leukaemia More trials…

    Learn about Rare Diseases

    Synovial sarcoma – Treatment Retinoblastoma Myxofibrosarcoma Ewing’s sarcoma – Life with Disease Encephalitis autoimmune – Life with Disease IgA nephropathy Carcinoid syndrome – Treatment Myelodysplastic syndrome with excess blasts – Treatment Hereditary motor and sensory neuropathy – Treatment Marfan’s syndrome – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Trametinib CANNABINOL ISPAGHULA HUSK Phenylalanine Elinzanetant Betula Alba Pollen Extract Bi 1819479 Gsk6097608 Ganirelix Ripretinib Tozorakimab Brexucabtagene Autoleucel Noradrenaline Tartrate TX000045 Sotorasib Cdr132L Permethrin Nesolicaftor Trastuzumab Emtansine Botensilimab More therapies…

    Learn about Your Condition

    Oesophageal disorder Atopic keratoconjunctivitis Delirium Food allergy Pigmentary glaucoma Niemann-Pick disease Urticaria Malignant fibrous histiocytoma Bladder cancer Marfan's syndrome Pulmonary tuberculosis Haemorrhage prophylaxis Transplant rejection Hypocalcaemia Breast cancer female More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Neuroendocrine carcinoma

  • Obrixtamig, Carboplatin, and Etoposide for First-Line Treatment of Advanced Extrapulmonary Neuroendocrine Carcinoma in DLL3-Positive Patients

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Neuroendocrine carcinoma
    Investigated Drugs:
    • Carboplatin
    • Etoposide
    • Igg-Like T Cell Engager Binding To Dll3 And Cd3
    Austria Belgium Czechia Denmark Finland France +8

  • Study of Tarlatamab for Patients with Metastatic or Advanced Small-Cell Lung Cancer and Neuroendocrine Carcinomas

    Recruiting

    2 1 1
    Investigated Diseases:
    • Small cell lung cancer metastatic
    • Neuroendocrine carcinoma
    Investigated Drugs:
    • Tarlatamab
    France Germany

  • Study of 64Cu-DOTATATE and 18F-FDG PET/CT imaging to predict disease progression in patients with neuroendocrine neoplasms

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Neuroendocrine carcinoma metastatic
    • Pancreatic neuroendocrine tumour metastatic
    • Small intestine neuroendocrine tumour
    Investigated Drugs:
    • Dotatate
    • Fludeoxyglucose (18F)
    • Copper (64Cu) Chloride
    Denmark

  • Study of Combined Imaging with Hyperpolarized [1-13C]Pyruvate and Fludeoxyglucose (18F) for Cancer Detection in Patients with Breast Cancer, Neuroendocrine Tumors, Lymphomas, or Sarcomas

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Neuroendocrine carcinoma metastatic
    • Pancreatic neuroendocrine tumour metastatic
    • Gastroenteropancreatic neuroendocrine tumour disease
    Investigated Drugs:
    • Fludeoxyglucose (18F)
    • Pyruvic Acid
    Denmark

  • Study on BI 764532 for Patients with Relapsed or Refractory Small Cell Lung Cancer and Other Neuroendocrine Carcinomas

    Recruiting

    2 1 1
    Investigated Diseases:
    • Small cell lung cancer
    • Neuroendocrine carcinoma
    Investigated Drugs:
    • Bi 764532
    • Igg-Like T Cell Engager Binding To Dll3 And Cd3
    Belgium Bulgaria France Germany Italy Poland +2

  • Study Comparing FOLFIRINOX and Cisplatin-Etoposide for Patients with Metastatic Gastroenteropancreatic Neuroendocrine Carcinoma

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Neuroendocrine carcinoma
    Investigated Drugs:
    • Irinotecan Hydrochloride Trihydrate
    • Cisplatin
    • Etoposide
    France
1 2
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!